Immunovant, Inc.

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage biopharmaceutical company focused on developing FcRn inhibitor therapies for autoimmune and immune-mediated diseases. The company entered the public markets in December 2019 through a business combination with Health Sciences Acquisitions Corporation, a healthcare-focused special purpose acquisition company sponsored by Health Sciences Acquisitions Partners. On August 31, 2020, Immunovant filed an S-1 registration statement with the SEC — accession number 0001193125-20-235301 — representing continued capital markets activity in the months following its de-SPAC transaction. The company operates in the biopharmaceutical sector and remains listed on Nasdaq. Sign up at SpacDesk for full filing histories, deal timelines, and comprehensive data across the SPAC universe.